COVID-19 Funding Snapshot for Pharma Developers/Manufacturers

Views as of August 7, 2020

Pharma Developers/Manufacturers

COVID-19 pharmaceutical funding landscape

COVID-19 funding has predominantly

COVID-19 drug development

U.S. funding is spread across

government vaccine supply deals

Though funding appears

Select funding deals across

US public deals with disclosed

US public deals with disclosed

Ex-US public deals

with disclosed values

Foundation deals with disclosed

Industry deals with disclosed

COVID-19 funding deals disclaimer

Contributing authors:

Tony Stripling, Associate Consultant
Sean Saunders, Life Sciences Speciaist
Jennifer Henry, Associate Consultant
Patrick Marquet, Associate

Related Insights

Contract/Pharma Services

Advancing Innovation and Global Reach: The Next Chapter in China’s Clinical Trial…

November 12, 2025

MedTech

Hospital Priorities 2025 China Edition: Key Findings for Medtech and Pharma Companies

June 20, 2025

Life Sciences & Pharma

Global Manufacturing Footprint Rationalization for a Leading Biopharmaceutical Company

March 31, 2025

A leading biopharmaceutical company engaged L.E.K. Consulting to optimize its global manufacturing network. The client sought to reduce costs while…

Life Sciences & Pharma

Unlocking Growth: Singapore's Role in Advancing Life Sciences and Medtech Innovations

March 10, 2025

Executive Insights

Life Sciences & Pharma

Aligning Aseptic Fill/Finish Operations With Global Pharmaceutical Demand

February 3, 2025

Executive Insights

Life Sciences & Pharma

Redefining Biopharma R&D Productivity: New Insights and Strategies

January 9, 2025